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Abstract
With aging of the HIV-infected population, non-AIDS conditions such as cardiovascular disease (CVD) now
account for substantial mortality and morbidity. While myocardial infarction is the major outcome of interest in
the field of HIV and CVD, cerebrovascular disease remains understudied, especially in the Southeastern United
States. We determined the incidence and clinical features of cerebrovascular events (CVE) in a large HIV clinical
cohort in North Carolina (NC). A total of 2,515 HIV-infected adults contributed a median of 4.5 years (IQR: 2.0,
7.8) of follow-up. Fifty-three CVEs were adjudicated for an incidence rate of 3.87 per 1,000 person-years (95% CI:
2.90, 5.06). The ischemic stroke incidence was 2.26 per 1,000 person-years (95% CI: 1.53, 3.21), approximately 1.5
times the rate of a population-based cohort in NC. At the time of CVE, the median age was 48 years (IQR: 42, 55).
Of ischemic strokes 76% resulted from large artery atherosclerosis or small vessel (lacunar) disease. In multi-
variable analyses, age, hypertension, dyslipidemia, recent CD4 + cell count £ 200 cells/mm3, and recent HIV
RNA > 400 copies/ml were associated with an increased risk of CVE. Antiretroviral therapy (ART) was not
associated with the risk of CVE. We concluded that in the post-ART era, HIV-infected individuals appear to be at
moderately increased risk of stroke. Prevention of CVEs in this population will require modification of tradi-
tional CVD risk factors and early, effective treatment of HIV infection.
Introduction
Due to the success of antiretroviral therapy (ART),the life expectancy among HIV-infected individuals has
increased and AIDS-related causes of death, namely opportu-
nistic infections (OI) and AIDS-defining cancers, have become
less common. With aging of the HIV-infected population, non-
AIDS conditions such as cardiovascular disease (CVD) now
account for substantial mortality and morbidity.1,2 For exam-
ple, compared to their uninfected counterparts, HIV-infected
adults appear to be at increased risk of myocardial infarction
(MI) and may experience MI at a younger age.3 Multiple factors
may contribute to a high CVD risk among HIV-infected per-
sons. Among HIV-infected persons, the vasculature may be
damaged by HIV itself through both generalized inflammation
as well as by direct infection and activation of T cells and
macrophages in the vascular lining.4,5 Moreover, among HIV-
infected adults in the US, there is a high prevalence of tradi-
tional CVD risk factors such as smoking, hypertension, and
dyslipidemia.3 It is likely that ART also plays a role in in-
creasing CVD risk, because although it effectively suppresses
viral replication and decreases inflammation, some anti-
retroviral agents predispose to diabetes and dyslipidemia re-
sulting in an increased CVD risk factor profile.6,7
While MI has been the major outcome of interest in the field
of HIV and CVD, cerebrovascular disease has remained rel-
atively understudied. In the setting of HIV infection, cere-
brovascular events (CVE) (including ischemic strokes,
hemorrhagic strokes, and transient ischemic attacks) have
diverse etiologies.8–10 In the pre-ART era, strokes related to
central nervous system (CNS) OIs made the independent
association of HIV infection and CVEs difficult to establish.11
As the incidence of CNS OIs decreased with ART, CVEs
were expected to become less frequent.12 Instead from 1997 to
2006, the proportion of HIV-infected persons who experi-
ence a stroke has increased.13 Recently, relying on adminis-
trative databases in Europe14 and an urban center in the
US,15 two studies found high stroke incidence rates among
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individuals known to be HIV-infected, compared to the
general population.
North Carolina (NC) is located in the Southeastern US,
which has been coined the ‘‘stroke belt’’ due to historically
high rates of stroke-related mortality.16 More recently the re-
gion was recognized to have the country’s highest rates of
new HIV infections.17 In this study we evaluated CVEs from
1999 to 2010 among HIV-infected patients participating in the
University of North Carolina (UNC) Center for AIDS Re-
search HIV Clinical Cohort (UCHCC) study. We estimated
CVE incidence rates, assessed the types and mechanisms of




All patients who received HIV primary care from 1999 to
2010 and enrolled in the UCHCC were included. As the major
public hospital in central NC, UNC provides care for HIV-
infected individuals from throughout the state, regardless of
socioeconomic or insurance status. The UCHCC study and
procedures have been described previously.18 Briefly, the
UCHCC includes demographic, clinical, and laboratory data
on all participants from electronic institutional records or
standardized medical record reviews. Dates of death are
ascertained using the NC vital records death certificates
and/or family report. For this study we excluded patients
with a known history of cerebrovascular disease at HIV care
initiation.
Adjudication of cerebrovascular events
As part of standardized medical record reviews that take
place every 6 months for the UCHCC, CVEs were recorded in
the database. For this study, each recorded CVE was adjudi-
cated by three clinicians (M.J.V., S.W., and D.Y.H.) using
paper and electronic medical records. Two blinded adjudi-
cators (M.J.V. and S.W.) used the WHO MONICA19 and the
American Heart Association criteria20 to confirm each CVE.
Disagreements between reviewers were resolved by a vas-
cular neurologist (D.Y.H.). Events that occurred in the setting
of organic brain lesions such as tumors, parasitic infections, or
progressive multifocal leukoencephalopathy were not classi-
fied as CVEs.
Confirmed CVEs were categorized as ischemic strokes,
subarachnoid hemorrhages, intracranial hemorrhages, or
transient ischemic attacks (TIAs). Both 28-day and 12-month
mortality were recorded. For each ischemic stroke, two stroke
specialists (S.W. and D.Y.H.) determined its probable mech-
anism using the TOAST criteria.21 To categorize the TOAST
mechanism (into large artery atherosclerosis, small vessel
disease, cardioembolic, other, or unable to classify), stroke
specialists reviewed CT and MRI/MRA reports (and images
when available), echocardiograms, carotid ultrasounds,
lumbar puncture results, and hypercoagulable tests.
An HIV-uninfected cohort at UNC was unavailable for
comparison; therefore, we compared our ischemic stroke rate
with published results from the NC site of the Atherosclerosis
Risk in Communities (ARIC) cohort.22 The ARIC cohort is a
population-based CVD study with one of four study sites in
central NC.
Study measures
Hypertension, diabetes, and hyperlipidemia were defined
either by clinician diagnosis or by the prescription of antihy-
pertensive, glucose-lowering, or cholesterol-lowering medica-
tions, respectively. Creatinine clearance (Crcl) was calculated
using the MDRD formula23 and chronic kidney disease was
defined as Crcl £ 60 for greater than 3 months.24 Coronary
artery disease was defined by physician diagnosis. Coinfection
with hepatitis C virus (HCV) and hepatitis B virus (HBV) were
defined by positive HCV antibody and HBV surface antigen,
respectively. Known behavioral risk factors for CVE (smoking,
intravenous (IV) drug use, cocaine, and alcohol abuse) were
recorded when reported by the provider and dichotomized to
‘‘ever’’ or ‘‘never.’’
CD4 + cell count and HIV RNA level were measured as
necessary for routine clinical care. CD4 + cell count nadir
was defined as the lowest recorded count during follow-up.
To minimize the impact of having an event on the mea-
surement of HIV-specific laboratory tests, the most recent
CD4 + cell count and HIV RNA level were defined as the
most proximal measurements at least 7 days prior to the
event or censor date.
Statistical analysis
Descriptive statistics were used to examine the distribu-
tion of demographics, comorbidities, and HIV-specific fac-
tors stratified by whether a patient experienced a CVE.
Follow-up was defined as the time from entry into the cohort
(at entry to care at the infectious diseases clinic or January 1,
1999) to the date of first CVE, death, or loss to follow-up
(LTFU). The incidence of CVE was calculated as the number
of confirmed events divided by the total contributed person-
years of follow-up. LTFU was defined as absence from the
clinic for 24 months. Participants remaining in care and
event-free were administratively censored on December 31,
2010.
The duration of ART was quantified using prescription
start and stop dates. We determined the impact of any current
ART on CVE risk and assessed the association of current
protease inhibitor (PI) use with CVE. In the analysis of CVE
rate in persons receiving PI versus nonnucleoside reverse
transcriptase inhibitor (NNRTI)-containing regimens, we ex-
cluded patients who received neither or both PI and NNRTI-
containing regimens during their follow-up.
To identify independent factors associated with having a
CVE, covariates examined in multivariable analyses using a
Poisson model included traditional stroke risk factors as well
as those factors found to have p value £ 0.2 on bivariable ana-
lyses. Statistical significance was determined using two-tailed
tests with p < 0.05 considered significant. Statistical analyses
were performed using STATA software (Version 11, StataCorp,
College Station, TX). This study received approval from the
UNC institutional review board.
Results
Study population
Of the 2,574 HIV-infected patients who met our study in-
clusion criteria, we excluded 59 (2%) with prevalent cerebro-
vascular disease at baseline. The median age at the start of
follow-up was 39 years (IQR: 32, 45); 70% were men and 58%
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were black (Table 1). At baseline the median CD4 + cell count
was 351 cells/mm3 (IQR: 144, 569), 46% had received ART,
and 27% had HIV RNA levels below 400 copies/ml.
The median duration of follow-up was 4.5 years (IQR: 2.0,
7.8) with patients contributing a total of 13,708 person-years
of follow-up. While under observation, 275 (11%) patients
died, 921 (37%) were lost to follow-up, and 1,266 (50%) re-
mained in care and event-free.
Cerebrovascular event rate and mechanisms
Fifty-three CVEs were confirmed during adjudication, re-
sulting in an incidence rate of 3.87 events per 1,000 person-
years (95% CI: 2.90, 5.06). The median age at time of CVE was
48 years (IQR: 42, 55) (Table 1). Ischemic strokes (n = 31) were
the most common type of CVE (Table 2) at an incidence of 2.26
per 1,000 person-years (95% CI: 1.53, 3.21).
Retrospective TOAST categorization of observed ischemic
strokes determined that 76% were caused by large artery
atherosclerosis or small vessel (lacunar) occlusion (Table 2).
Only one ischemic stroke occurred as a result of a possible OI.
In that case, a 35-year-old man with a CD4 + cell count of 1 cell/
mm3 and HIV RNA of 750,000 copies/ml presented with
stroke symptoms. White matter lesions found on imaging
were suspicious for a CNS OI. However, the patient died
before the etiology of the lesions could be identified. In three
ischemic strokes (10%), we could not identify the mechanism.
Two patients (4%) died within 28 days of their event (one
from a massive ICH and one from anoxic brain injury due to
cardiogenic shock). The 12-month mortality rate was 15%
overall (ranging from 0% for TIA to 50% for ICH).
Evaluation of risk factors
In bivariable analyses, demographic and HIV clinical and
treatment characteristics, as well as comorbid conditions were
Table 1. Characteristics of the HIV Clinical Cohort and of Cohort Participants





CVE (n = 53)
Age at baseline in years, n (%)
< 40 1,349 (54) 18 (34)
40–50 841 (33) 19 (36)
> 50 325 (13) 16 (30)
Age at time of event, median years (IQR) NA 48 (42–55)
Male sex, n (%) 1,724 (70) 32 (60)
Race/ethnicity, n (%)
Black 1,458 (58) 34 (64)
White 806 (32) 16 (30)
Othera 251 (10) 3 (6)
HIV risk factor, n (%)
MSM 1,017 (40) 11 (21)
IVDU 339 (14) 14 (26)
Heterosexual sex 1,409 (56) 35 (66)
Hepatitis B coinfection, n (%) 119 (4.7) 4 (8)
Hepatitis C coinfection, n (%) 405 (16) 16 (30)
CD4 + cell count nadir, median cells/mm3 (IQR) 235 (69–407) 121 (43–300)
Most recent CD4 + cell count, median cells/mm3 (IQR) 466 (260–700) 267 (96–530)
Baseline HIV RNA > 400 copies/ml, n (%) 1,787 (73) 42 (79)
Most recent HIV RNA, > 400 copies/ml, n (%) 992 (40) 30 (57)
Antiretroviral therapy use, n (%) 2,239 (89) 50 (94)
Duration of follow-up, median years (IQR) 4.5 (2.5–7.9) 3.3 (1.9–6.7)
Entered cohort since 1999, n (%) 1,840 (73) 23 (43)
aHispanic (5%), American Indian (2%), and unknown (3%).
CVE, cerebrovascular event; IQR, interquartile range; MSM, men who have sex with men; IVDU, intravenous drug use.
Table 2. Types of Cerebrovascular Events (n = 53)
and Mechanisms of Ischemic Stroke (n = 31)
Among HIV -Infected Individuals
n (%)
Type of event
Ischemic stroke 31 (58)
Transient ischemic attack 12 (23)
Intracerebral hemorrhage 9 (17)
Unable to determine 1 (2)
Mechanisms of ischemic strokesa
Large artery atherosclerosis 13 (42)
Small vessel (lacunar) occlusion 11 (35)
Cardioembolism 1 (3)
Stroke of other determined etiologyb 3 (10)
Stroke of undetermined etiologyc 3 (10)
aUsing TOAST criteria.21
bOther determined etiologies included cocaine-induced vaso-
spasm, stump syndrome, and white matter lesions suspected but
not confirmed to be caused by a CNS OI.
cInsufficient records available or incomplete work-up.
1070 VINIKOOR ET AL.
associated with increased CVE incidence rates (Table 3).
Specifically, older patients and those with lower CD4 + cell
counts, detectable HIV RNA levels, hypertension, diabetes,
dyslipidemia, coronary artery disease, and HCV coinfection
were all at greater CVE risk. While CD4 + cell count nadir
£ 200 cells/mm3 was not associated with CVE (IRR 1.31, 95%
CI: 0.76, 2.26), most recent CD4 + cell count £ 200 cells/mm3
was associated with a 3-fold increased rate of CVE (IRR 3.36,
95% CI: 1.92, 5.88). Overall, current ART was not associated
with increased risk (Table 3). Current receipt of PI-containing
regimens (in 1,164 patients), when compared to NNRTI-
containing ART (in 795 patients), did not increase the rate of
events (IRR 1.46, 95% CI: 0.52, 4.08). During follow-up, 40% of
patients reported smoking; however, smoking did not in-
crease CVE risk. Similarly, IV drug use, alcohol abuse/
dependency, or cocaine use showed no association with
CVE risk.
Age, hypertension, dyslipidemia, recent CD4 + cell count
£ 200 cells/mm3, and recent detectable HIV RNA level were
independently associated with CVE (all p < 0.05) (Table 4).
Table 3. Demographic Characteristics, Traditional Cardiovascular Disease Risk Factors,




No. events per 1,000 PYs
Totals 53/13,708 3.87
Incidence rate
ratio (95% CI) p
Demographics
Age at baseline in years
> 50 16/1,461 10.95 2.15 (1.53, 3.01) < 0.01
40–50 19/4,723 4.02 0.92 (0.80, 1.04)
< 40 18/7,577 2.38 Referent
Female sex 21/4,169 5.04 1.51 (0.87, 2.62) 0.14
Black race (vs. other)b 34/7,924 4.29 1.32 (0.75, 2.31) 0.34
Comorbidities
Hypertension 37/7,358 5.03 3.01 (1.67, 5.41) < 0.01
Diabetes 11/1,976 5.57 2.00 (1.03, 3.88) 0.04
Dyslipidemia 26/5,269 4.93 2.56 (1.49, 4.38) < 0.01
Chronic kidney disease 11/2,718 4.05 1.45 (0.75, 2.82) 0.27
Coronary artery disease 6/751 7.99 4.51 (1.21, 16.75) 0.03
Hepatitis C coinfection 16/2,384 6.71 2.15 (1.20, 3.87) 0.01
Hepatitis B coinfection 4/819 4.88 1.82 (0.66, 5.05) 0.25
HIV-specific factors
CD4 nadir £ 200 cells/mm3 31/7,136 4.34 1.31 (0.76, 2.26) 0.34
Most recent CD4 £ 200 cells/mm3 20/2,148 9.31 3.36 (1.92, 5.88) < 0.01
Most recent HIV RNA
> 400 copies/mL
30/4,291 6.99 2.83 (1.64, 4.87) < 0.01
Antiretroviral therapy use 50/12,934 3.86 2.13 (0.67, 6.84) 0.20
PI vs. NNRTI usec 21/6,855 3.06 1.46 (0.52, 4.08) 0.47
aPY, person-year.
bThere was no difference in CVE rate between other race/ethnicities.
cPI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; analysis included only patients who received solely PI-based
(N = 1164) or NNRTI-based (N = 795) regimens.
Table 4. Factors Independently Associated with Risk of Cerebrovascular Events
Among HIV-Infected Individuals
Full modela Final modelb
IRR (95% CI) p IRR (95% CI) p
Age (per 10 year increase) 1.78 (1.25, 2.55) < 0.01 1.72 (1.29, 2.28) < 0.01
Female sex 1.69 (0.82, 3.48) 0.16
Black race 0.89 (0.46, 1.74) 0.73
Hypertension 1.96 (0.99, 3.99) 0.05 2.04 (1.08, 3.87) 0.03
Diabetes 0.95 (0.42, 2.18) 0.91
Dyslipidemia 3.02 (1.48, 6.17) < 0.01 2.94 (1.63, 5.32) < 0.01
Coronary artery disease 2.51 (0.62, 10.17) 0.20
Tobacco smoking 0.81 (0.40, 1.65) 0.56
Hepatitis C coinfection 1.81 (0.85, 3.84) 0.12
Most recent CD4 < 200 cells/mm3 2.83 (1.27, 6.33) 0.01 2.69 (1.47, 4.91) < 0.01
Most recent HIV RNA > 400 copies/mL 3.97 (1.90, 8.31) < 0.01 3.56 (1.94, 6.53) < 0.01
Antiretroviral therapy use 4.16 (0.80, 21.65) 0.09
aRisk factors in the full Poisson regression model were selected a priori or after bivariable analyses.
bFull model was reduced based on p > 0.05 to reach the final model.
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Independent of age, dyslipidemia, CD4 + cell count, and HIV
RNA level, patients with hypertension had twice the rate of
CVE (IRR 2.04, 95% CI: 1.08, 3.87). Having a detectable HIV
RNA level at the most recent measurement was associated
with more than a 3-fold increased rate of CVE (IRR 3.56, 95%
CI: 1.94, 6.53), independent of age, hypertension, dyslipide-
mia, and CD4 + cell count. In a sensitivity analysis that re-
stricted the sample to patients with a viral load measurement
within 90 days of the event, censoring, or death, the incidence
rate ratio increased to 4.81. Exclusion of patients who entered
care at UNC prior to the cohort inception (27%) from the
analysis did not change the results.
Discussion
Among HIV-infected adults receiving care at the UNC
Hospital, we estimated the overall incidence of CVE at 3.87
per 1,000 person-years and the incidence of ischemic strokes
at 2.26 per 1,000 person-years. At the time of CVE, patients
had a median age of 48 years. Both traditional CVD risk fac-
tors (hypertension and dyslipidemia) and HIV-specific factors
(recent CD4 + cell count and HIV viral load) were associated
with the risk of CVE. Our cohort study is the first to investi-
gate the clinical epidemiology of CVE among HIV-
infected persons living in the Southeastern United States.
Stroke incidence rates among HIV-infected adults in NC
are slightly different from other HIV-infected populations. In
Europe, HIV-infected adults have a slightly lower CVE inci-
dence than we recorded, consistent with lower rates seen in
the general population of Europe compared to the US.14,25–27
Among HIV-infected populations in the US, two studies re-
ported somewhat higher incidence rates than seen in our co-
hort. The Veterans Aging Cohort Study (VACS) reported a
stroke rate of 2.93 per 1,000 person-years in HIV monoinfected
and 6.99 per 1,000 person-years in HIV/HCV coinfected pa-
tients.28 The VACS consists of military veterans who have a
high prevalence of comorbidities and behavioral risk factors
that have been associated with stroke. Partners Healthcare in
Boston, which utilized a large administrative database, esti-
mated the incidence of ischemic strokes at 5.27 per 1,000
person-years.15 Administrative cohorts that rely on ICD-9
codes are valuable in the study of rare events but can be prone
to low specificity.29 Therefore, in the Boston study, a clinician
reviewed events to improve the accuracy of their estimate.14,15
In addition to variability in CVE rates by population, CVE
incidence appears to vary by HIV status. In Denmark and
Boston, HIV-infected individuals had approximately 1.5
times the rate of CVE compared to the general population
(Fig. 1).14,15 One limitation to our study was our inability to
directly compare our stroke rates to an HIV-uninfected cohort
at our institution. However, we compared our results to the
NC site of the ARIC cohort, whose demographically mixed
population is representative of NC. In NC, individuals aged
45–84 years old (followed from 1987 to 1995) had an age-
adjusted incidence of ischemic strokes of 1.41 per 1,000 per-
son-years (95% CI: 0.99, 2.01),22 approximately two-thirds the
rate seen in our cohort. Participants aged 45–54 across all sites
of the ARIC cohort from 1987 to 2001 had a rate of ischemic
stroke of 1.18 per 1,000 person-years,30 approximately one-
third the rate seen in 40–50 year olds in our cohort. Because of
differences in the timing, design, and adjudication between
ARIC and our study, we cannot be certain that the difference
in CVE rates is due to HIV infection. However, our results, in
conjunction with two recently published studies,14,15 suggest
that HIV-infected individuals may be at increased risk of
CVE. The fact that a low CD4 cell count and detectable plasma
HIV RNA level were associated with stroke in the multivar-
iable analysis supports the plausibility of this relationship.
Among patients who experienced a CVE, ICH accounted
for approximately 20% of events, which compares to 10% re-
ported in the general population.30 However, the 28-day
mortality after hemorrhagic stroke was only 7.7% in this study
versus 37.5% in the ARIC cohort.22 Consistent with the gen-
eral population, the majority of ischemic strokes in this study
resulted from large artery atherosclerosis and small vessel
disease (Table 2). We observed a very small number of events
caused by CNS OIs, which is similar to other HIV studies done
after ART became widely available in the United States and
Europe.9,26 We did not identify any cases of HIV-associated
vasculopathy, which is a poorly characterized condition that
manifests as fusiform intracranial aneurysmal disease in HIV-
infected persons.8 Although two stroke specialists partici-
pated in the adjudication process, we acknowledge the diffi-
culty in accurate assignment of TOAST categorization, which
is most accurate when utilized in prospective studies that have
consistent and comprehensive diagnostic work-ups. Due to
the retrospective nature of this study, diagnostic testing pat-
terns were variable, and in some cases adjudicators relied on
radiology reports when images were not available for review.
While we confirmed that among our HIV-infected cohort
traditional risk factors are the key targets for prevention of
CVD, viremia and immunosuppression should also be
viewed as modifiable risk factors. Consistent with other ob-
servational studies,31,32 viral load was associated with the risk
of an event in our analysis. Systemic inflammation as a con-
sequence of uncontrolled viremia, has been linked with car-
diovascular events. In the SMART study, HIV-infected
patients with high CD4 + cell counts randomized to a viremia
permissive strategy had an increased risk of CVD compared
to those who were virologically suppressed.33 Recently in an
observational cohort of ART-treated patients, episodes of
high-level viremia predicted cardiovascular events.34 In light
of emerging evidence regarding the harm of uncontrolled
FIG 1. Ischemic stroke rates in HIV-infected and compari-
son cohorts from a Boston-area health care system (left),15
from NC [in the UNC Center for AIDS Research HIV Clinical
Cohort (UCHCC) and Atherosclerosis Risk in Communities
(ARIC) Cohort] (center),29 and from a Danish nationwide
population-based cohort (right).14
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viremia, HIV treatment guidelines in the US now support
initiating ART earlier in the course of HIV infection.35 Further
investigation should evaluate the role of virologic suppres-
sion in the prevention of CVD.
While ART-induced virologic suppression could modify
the risk of CVD, certain antiretroviral agents have been linked
with an increased risk of MI.25,36 This association has not been
established for ART and stroke. One of the strengths of this
study was our ability to utilize both the duration and timing
of ART exposure in our Poisson models. Overall, we did not
find a significant association between ART use and risk of
CVE. PIs can increase the CVD risk profile by predisposing
patients to major CVD risk factors including hyperglycemia,
dyslipidemia, and metabolic syndrome.6,37 We compared
patients who received PI versus NNRTI-based regimens
(which were protective for CVE in a prior study15) and found
that in our study population, PI exposure did not predict in-
creased the risk of CVE. The lack of association between PI
exposure and CVE has been previously reported15 and may
be due to differences in the pathogenesis of MI and CVE in
HIV-infected individuals.
The major strength of this study was the use of a large
clinical cohort study located in the Southeastern US with
comprehensive patient data coupled with systematic event
adjudications by our clinical and research team. We captured
events that presented to both the inpatient and outpatient
setting as well as events initially managed at outside hospi-
tals. This minimized the chance of underestimating the event
rate. Because stroke and other non-AIDS conditions can be
inaccurately coded in the medical record,29,38,39 we confirmed
each event with at least two blinded adjudicators and utilized
stroke specialists. While we identified and adjudicated all
events that occurred during follow-up, LTFU was quite high
(37%) and could have affected our observed incidence rate.
Although patients in UCHCC are demographically similar to
HIV-infected individuals receiving care in NC, as a public and
tertiary care medical facility, UNC may provide care dispro-
portionately to HIV patients with lower income and more
advanced disease compared to the HIV-infected population in
NC. Because low SES and advanced HIV disease have been
associated with CVE, our observed incidence rate may not be
generalizable to all North Carolinians living with HIV/AIDS.
In summary, CVEs are uncommon but potentially life-
threatening events for which persons living with HIV infec-
tion may be at modestly increased risk. In the post-ART era,
the mechanisms and risk factors for CVE among HIV-infected
adults appear to mirror those of the general population.
Modification of traditional risk factors should be a focus of
CVD prevention in HIV clinics. ART does not appear to in-
crease the risk of CVE; instead, early ART and viral sup-
pression may be an adjunctive approach to prevention.
Acknowledgments
This research was supported by the University of North
Carolina at Chapel Hill Center for AIDS Research (CFAR), an
NIH-funded program P30 AI 50410. M.J.V. was supported by
NIH Training Grant 5T32 AI07001-35.
Author Disclosure Statement
No competing financial interests exist.
References
1. Achhra AC, Amin J, Law MG, et al.: Immunodeficiency and
risk of serious clinical endpoints in a well studied cohort of
treated HIV-infected patients. AIDS 2010;24:1877–1886.
2. Sackoff JE, Hanna DB, Pfeiffer MR, et al.: Causes of death
among persons with AIDS in the era of highly active anti-
retroviral therapy: New York City. Ann Intern Med 2006;
145:397–406.
3. Triant VA, Lee H, Hadigan C, et al.: Increased acute myo-
cardial infarction rates and cardiovascular risk factors
among patients with human immunodeficiency virus dis-
ease. J Clin Endocrinol Metab 2007;92:2506–2512.
4. Bukrinsky M and Sviridov D: HIV and cardiovascular dis-
ease: Contribution of HIV-infected macrophages to devel-
opment of atherosclerosis. PLoS Med 2007;4:e43.
5. Eugenin EA, Morgello S, Klotman ME, et al.: Human im-
munodeficiency virus (HIV) infects human arterial smooth
muscle cells in vivo and in vitro: Implications for the path-
ogenesis of HIV-mediated vascular disease. Am J Pathol
2008;172:1100–1111.
6. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and
the prevalence and incidence of diabetes mellitus in the
multicenter AIDS cohort study. Arch Intern Med
2005;165:1179–1184.
7. Friis-Møller N, Weber R, Reiss P, et al.: Cardiovascular disease
risk factors in HIV patients–association with antiretroviral
therapy. Results from the DAD study. AIDS 2003;17:1179–1193.
8. Tipping B, de Villiers L, Wainwright H, et al.: Stroke in
patients with human immunodeficiency virus infection.
J Neurol Neurosurg Psychiatry 2007;78:1320–1324.
9. Ortiz G, Koch S, Romano JG, et al.: Mechanisms of ischemic
stroke in HIV-infected patients. Neurology 2007;68:1257–1261.
10. Connor MD, Lammie GA, Bell JE, et al.: Cerebral infarction
in adult AIDS patients: Observations from the Edinburgh
HIV autopsy cohort. Stroke 2000;31:2117–2126.
11. Pinto AN: AIDS and cerebrovascular disease. Stroke.
1996;27:538–543.
12. d’Armihio Monforte A, Cinque P, Mocroft A, et al.: Chan-
ging incidence of central nervous system diseases in the
EuroSIDA cohort. Ann Neurol 2004;55:320–328.
13. Ovbiagele B and Nath A: Increasing incidence of ischemic
stroke in patients with HIV infection. Neurology
2011;76:444–450.
14. Rasmussen LD, Engsig FN, Christensen H, et al.: Risk of
cerebrovascular events in persons with and without HIV: A
Danish nationwide population-based cohort study. AIDS
2011;25:1637–1646.
15. Chow FC, Regan S, Feske S, et al.: Comparison of ischemic
stroke incidence in HIV-infected and non-HIV-infected pa-
tients in a US health care system. J Acquir Immune Defic
Syndr 2012;60:351–358.
16. Casper ML, Barnette E, Williams GIJ, et al.: Atlas of Stroke
Mortality: Racial, Ethnic, and Geographic Disparities in the United
States. Center for Disease Control and Prevention, 2003.
17. Centers for Disease Control and Prevention: HIV Surveillance
Report, 2009, 2011.
18. Napravnik S, Eron JJ Jr., McKaig RG, et al.: Factors associ-
ated with fewer visits for HIV primary care at a tertiary
care center in the Southeastern U.S. AIDS Care 2006;
18 Suppl 1:S45–50.
19. The World Health Organization MONICA Project (moni-
toring trends and determinants of cardiovascular disease): A
major international collaboration. WHO MONICA Principal
Investigators. J Clin Epidemiol 1988;41:105–114.
STROKE IN HIV-INFECTED ADULTS IN NORTH CAROLINA 1073
20. Easton JD, Saver JL, Albers GW, et al.: Definition and eval-
uation of transient ischemic attack. Stroke 2009;40:2276–
2293.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, et al.: Classification
of subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial. Stroke 1993;24:35–41.
22. Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke
incidence and survival among middle-aged adults: 9-year
follow-up of the atherosclerosis risk in communities (ARIC)
cohort. Stroke 1999;30:736–743.
23. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method
to estimate glomerular filtration from serum creatinine: A
new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann Intern Med 1999;130:461–470.
24. Levey AS, Eckardt K, Tsukamoto Y, et al.: Definition and
classification of chronic kidney disease: A position statement
from Kidney Disease: Improving Global Outcomes (KDI-
GO). Kidney Int 2005;67:2089–2100.
25. Writing committee of the D:A:D study group: Cardio- and
cerebrovascular events in HIV-infected persons. AIDS
2004;18:1811–1817.
26. Corral I, Quereda C, Moreno A, et al.: Cerebrovascular is-
chemic events in HIV-1-infected patients receiving highly
active antiretroviral therapy: Incidence and risk factors.
Cerebrovasc Dis 2009;27:559–563.
27. Truelsen T, Piechowski-Jozwiak B, Bonita R, et al.: Stroke
incidence and prevalence in Europe: A review of available
data. Eur J Neurol 2006;13:581–598.
28. Sico J, Chang J, Freiberg M, et al.: HIV infection, hepatitis C
infection, and risk of stroke in the veterans aging cohort study
virtual cohort (VACS-VC). Paper presented at the Conference
on Retroviruses and Opportunistic Infections, 2010.
29. Leibson CL, Naessens JM, Brown RD, et al.: Accuracy of
hospital discharge abstracts for identifying stroke. Stroke
1994;25:2348–2355.
30. National Heart Lung and Blood Institute: Incidence and Pre-
valence: 2006 Chart Book on Cardiovascular and Lung Diseases.
Bethesda, Maryland, 2006.
31. The antiretroviral therapy cohort collaboration (ART-CC
writing committee): Causes of death in HIV-1 infected
patients treated with antiretroviral therapy, 1996–2006:
Collaborative analysis of 13 HIV cohort studies. Clin Infect
Dis 2010;50:1387–1396.
32. Marin B, Thiebaut R, Bucher HC, et al.: Non-AIDS-defining
deaths and immunodeficiency in the era of combination
antiretroviral therapy. AIDS 2009;13:1743–1753.
33. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4 + count-
guided interruption of antiretroviral treatment. N Engl J
Med 2006;355:2283–2296.
34. Zhang S, van Sighem A, Kesserling A, et al.: Episodes of HIV
viremia and the risk of non-AIDS diseases in patients on
suppressive antiretroviral therapy. J Acquir Immune Defic
Syndr 2012;60:265–272.
35. Panel on antiretroviral guidelines for adults and adolescents:
Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected
Adults and Adolescents. Department of Health and Human
Services, 2012.
36. Friis-Møller N, Sabin CA, Weber R, et al.: Combination an-
tiretroviral therapy and the risk of myocardial infarction. N
Engl J Med 2003;349:1993–2003.
37. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipide-
mia in HIV-infected individuals treated with protease in-
hibitors. The Swiss HIV Cohort Study. Circulation 1999;100:
700–705.
38. Lifson AR, INSIGHT Endpoint Review Committee Writing
Group, Belloso WH, et al.: Development of diagnostic crite-
ria for serious non-AIDS events in HIV clinical trials. HIV
Clin Trials 2010;11:205–219.
39. Goldstein LB: Accuracy of ICD-9-CM coding for the identi-
fication of patients with acute ischemic stroke: Effect of
modifier codes. Stroke 1998;29:1602–1604.
Address correspondence to:
Sonia Napravnik
Center for Infectious Diseases
University of North Carolina
130 Mason Farm Road
2nd Floor Bioinformatics Building
Chapel Hill, North Carolina 27599-7030
E-mail: sonia_napravnik@med.unc.edu
1074 VINIKOOR ET AL.
